Alignment Healthcare LLC
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Alignment Healthcare LLC.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 8.70 $ to 24.60 $ · Last price: 8.70 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Healthcare Plans
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Alignment Healthcare LLC ALHC | 1.8 | 84.9 | 20.6 | 12.6 | 1.3 | 46.1 | -47.8 |
| UnitedHealth Group Incorporated UNH | 338.6 | 29.6 | 14.9 | 19.7 | 8.1 | 11.8 | 12.8 |
| CVS Health Corp CVS | 115.6 | 40.1 | 13.7 | 13.6 | 4.1 | 7.9 | 25.9 |
| Elevance Health Inc ELV | 89.9 | 17.7 | 0.0 | 26.0 | 5.3 | 12.6 | 37.0 |
| Cigna Corp CI | 72.8 | 11.9 | 7.7 | 9.1 | 5.5 | 11.3 | -4.8 |
| Humana Inc HUM | 46.3 | 41.8 | 0.0 | 13.7 | 4.7 | 10.1 | 43.3 |
| Centene Corp CNC | 33.1 | – | 3.9 | 11.4 | 5.1 | 19.4 | 107.6 |
| Molina Healthcare Inc MOH | 10.7 | 59.7 | 16.7 | 8.4 | 1.7 | 11.8 | 16.3 |
| Oscar Health Inc OSCR | 9.2 | – | 0.0 | 20.2 | 15.2 | 27.5 | 80.0 |
| Median of companies shown | 46.3 | 40.1 | 7.7 | 13.6 | 5.1 | 11.8 | 25.9 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2019 | 757 | -29 | -45 | -0.29 | 9 | -79 | 193 |
| 2020 | 959 | -5 | -23 | -0.12 | 8 | 31 | 339 |
| 2021 | 1,168 | -178 | -195 | -1.14 | -79 | 306 | 631 |
| 2022 | 1,434 | -129 | -150 | -0.83 | -45 | 238 | 634 |
| 2023 | 1,824 | -128 | -148 | -0.79 | -59 | 157 | 592 |
| 2024 | 2,704 | -102 | -128 | -0.67 | 35 | 100 | 782 |
| 2025 | 3,949 | 15 | -1 | 0.00 | 140 | 179 | 1,066 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.16 | – | 701 | 50.70 | -4.40 | -9 | -18 |
| 2025: Q1 | -0.05 | – | 927 | 47.50 | -1.00 | 17 | 8 |
| 2025: Q2 | 0.07 | – | 1,015 | 49.00 | 1.50 | 29 | 21 |
| 2025: Q3 | 0.02 | – | 994 | 43.50 | 0.40 | 145 | 161 |
| 2025: Q4 | -0.05 | – | 1,013 | 44.40 | -1.10 | -50 | -67 |
| 2026: Q1 | 0.05 | – | 1,235 | 33.30 | 0.90 | 129 | 121 |
| 2026: Q2 | 0.17 | 142.90 | 1,336 | 31.50 | 2.70 | -17 | -27 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 10 of our scanner strategies — each hit links to the scanner.
Growth
Quality & Balance Sheet
Breakout & Setup
Earnings & Surprises
Momentum & Trend
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.50 | 0.49 – 0.50 | 5,215 | 54.0% | 4 |
| 12/31/2027 | 0.75 | 0.68 – 0.87 | 6,500 | 52.0% | 4 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Instead of guessing what the stock is worth, we turn the question around: what free cash flow growth has to happen for today’s market value to add up? The assumptions behind it can be moved.
Today’s market value implies roughly -4.0% growth in free cash flow per year over ten years (assumptions: discount rate 10.0%, terminal growth 2.5%).
| Free cash flow (last twelve months) | $205.5M |
|---|---|
| Market cap | $1.77B |
| Free cash flow in year ten | $136.6M |
| Terminal value as a share of market value | 40.7% |
It shows which assumption is built into today’s price, not whether that assumption will hold. Every assumption can be changed with the sliders; the figures move with them.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Alignment Healthcare setzt KI laut eigenen SEC-Berichten operativ in der firmeneigenen Technologieplattform AVA ein: Maschinelles Lernen und künstliche Intelligenz prognostizieren Krankenhaus-Einweisungen, Wiedereinweisungsrisiken, Mitglieder-Zufriedenheit und Kündigungsrisiken, um die Versorgung der Medicare-Advantage-Mitglieder zu steuern. KI ist damit ein internes Werkzeug zur Kostensteuerung und Versorgungskoordination, aber keine eigene Umsatzquelle - das Unternehmen verkauft Krankenversicherung, keine KI-Produkte. Die Risikofaktoren nennen den eigenen KI-Einsatz zudem ausdrücklich als operatives, regulatorisches und rechtliches Risiko, was den Befund „nutzt“ (statt „verkauft“ oder „bedroht“) stützt.
View the full file — quotes, sources, reviewed filings
„Our internal care teams and external providers use AVA, our proprietary technology platform, to coordinate high-quality care for members and manage the complexity of the healthcare system."
Unsere internen Versorgungsteams und externen Leistungserbringer nutzen AVA, unsere firmeneigene Technologieplattform, um eine hochwertige Versorgung der Mitglieder zu koordinieren und die Komplexität des Gesundheitssystems zu bewältigen.
10-K · 2026-02-27 · View SEC filing
„It also uses machine learning and artificial intelligence to help predict various scenarios such as hospital admission and re-admission risk, member satisfaction, disenrollment risk and various disease propensity scores and how to best intervene."
Sie [die AVA-Plattform] nutzt zudem maschinelles Lernen und künstliche Intelligenz, um verschiedene Szenarien vorherzusagen - etwa das Risiko von Krankenhaus-Einweisungen und Wiedereinweisungen, die Mitglieder-Zufriedenheit, das Kündigungsrisiko und diverse Krankheits-Wahrscheinlichkeitswerte - sowie um zu bestimmen, wie am besten einzugreifen ist.
10-K · 2026-02-27 · View SEC filing
„Our use of machine learning and artificial intelligence, including within our AVA platform, may introduce operational, regulatory and legal risks that could adversely affect our business, financial condition and results of operations."
Unser Einsatz von maschinellem Lernen und künstlicher Intelligenz, auch innerhalb unserer AVA-Plattform, kann operative, regulatorische und rechtliche Risiken mit sich bringen, die unser Geschäft, unsere Finanzlage und unsere Geschäftsergebnisse beeinträchtigen könnten.
10-K · 2026-02-27 · View SEC filing
Filings Reviewed: 10-Q 2026-04-30 · 10-Q 2025-10-30 · 10-Q 2025-07-30 · 10-Q 2025-05-01 · 10-K 2026-02-27 · 10-K 2025-02-27
Rated on July 10, 2026 · How the Rating Is Built
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 40.2%
- More than 10% revenue growth is expected for the coming year 25.5%
- Share count grows by less than 3% a year 3.0%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 48.9%
- Gross margin at 40% or higher and without meaningful erosion 12.4%
- Goodwill from acquisitions does not grow faster than revenue 3.0%
- Net debt below twice EBITDA 275 m net cash
- Operating cash flow covers the profits of the last three years 392 m
- Return on capital at 15% or higher, or up versus two years ago 2.9%
- Insiders hold at least 10% or are net buyers 2.8%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
6/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 31.7%
- Exp. sales growth 3Y > 5% 28.3%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 28.3%
- Net debt < 4x EBIT -18.6x
- EBIT positive, 10Y straight 1
- Max. EBIT decline < 50% 0.0%
- Return on equity > 15% -0.5%
- ROCE > 15% 2.9%
- Expected return > 10% 36.5%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | Kao John E | Chief Executive Officer | Sell | 27,400 | 13.00 | 356,200 |
| Sep 11, 2026 | Maroney Dawn Christine | President | Sell | 122,707 | 12.68 | 1,555,925 |
| Sep 11, 2026 | Kao John E | Chief Executive Officer | Sell | 385,270 | 12.68 | 4,885,224 |
| Sep 10, 2026 | Kao John E | Chief Executive Officer | Sell | 172,600 | 12.96 | 2,236,447 |
| Aug 14, 2026 | Maroney Dawn Christine | President | Sell | 5,000 | 14.00 | 70,000 |
| Aug 10, 2026 | Kao John E | Chief Executive Officer | Sell | 298,000 | 13.88 | 4,136,776 |
| Jul 15, 2026 | Maroney Dawn Christine | President | Sell | 177,068 | 20.83 | 3,687,990 |
| Jul 15, 2026 | Maroney Dawn Christine | President | Other | 152,068 | 9.06 | 1,377,736 |
| Jul 10, 2026 | Kao John E | Chief Executive Officer | Sell | 18,356 | 20.65 | 378,998 |
| Jul 10, 2026 | Kao John E | Chief Executive Officer | Sell | 279,644 | 19.81 | 5,540,363 |
The company
About the Company
Alignment Healthcare, Inc. betreibt eine verbraucherorientierte Gesundheitsplattform für Senioren in den USA.
- CEO Insider Trades (12 Mo.)
- selling own stock
- Employees
- 1,849
- Headquarters
- Orange, CA
- Address
- 1100 West Town and Country Road, 92868 Orange, United States
- Phone
- 844 310 2247
- Website
- alignmenthealth.com
- IPO Date
- 03/26/2021
- ISIN
- US01625V1044
Management
| Name | Title | Birth Year |
|---|---|---|
| John E. Kao | Founder, Chairman & CEO | 1962 |
| Joseph Samuel Konowiecki J.D. | Vice Chairman & Executive VP of Corporate Affairs | 1954 |
| Dawn Christine Maroney | President | 1968 |
| James M. Head | Chief Financial Officer | 1966 |
| Christopher J. Joyce J.D. | Chief Legal & Administrative Officer | 1964 |
| Hyong J. Kim M.D. | Chief Medical Officer | 1970 |
| Donald S. Furman M.B.A., M.D. | Co-Founder & Chief Clinical Officer | 1951 |
| Shane Hochradel | Chief Operations Officer | – |
| Robert L. Scavo | Chief Information Officer | 1965 |
| Andreas Wagner | Chief Human Resources Officer | 1970 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 07/30/2026 Alignment Healthcare, Inc. (ALHC): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.